Litcius/Paper detail

A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

Christoph K. Stein‐Thoeringer, Neeraj Saini, Eli Zamir, Viktoria Blumenberg, Maria‐Luisa Schubert, Uria Mor, Matthias Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia‐Chi Chang, Lauren McDaniel, Ivonne I. Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis Fayad, Sairah Ahmed, Swaminathan P. Iyer, Raphaël Steiner, Preetesh Jain, Loretta J. Nastoupil, Jason R. Westin, Reetakshi Arora, Michael Wang, Joel G. Turner, Meghan Menges, Melanie J. Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Müller‐Tidow, Frederick L. Locke, Marco L. Davila, Richard E. Champlin, Christopher R. Flowers, Elizabeth J. Shpall, Hendrik Poeck, Sattva S. Neelapu, Michael Schmitt, Marion Subklewe, Michael D. Jain, Robert R. Jenq, Eran Elinav

2023Nature Medicine227 citationsDOIOpen Access PDF

Topics & Concepts

AkkermansiaMicrobiomeAntibioticsImmunologyMedicineCancerCohortPopulationGut floraInternal medicineBiologyOncologyBioinformaticsBacteroidesMicrobiologyBacteriaGeneticsEnvironmental healthCAR-T cell therapy researchCancer Immunotherapy and Biomarkers
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy | Litcius